dipyridamole has been researched along with Alcoholic Liver Diseases in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kryzhanovski, VA | 1 |
| Beller, GA | 1 |
1 other study available for dipyridamole and Alcoholic Liver Diseases
| Article | Year |
|---|---|
Usefulness of preoperative noninvasive radionuclide testing for detecting coronary artery disease in candidates for liver transplantation.
Topics: Coronary Disease; Dipyridamole; Dobutamine; Exercise Test; Female; Heart; Humans; Liver Diseases, Al | 1997 |